For the past 30 years, adoptive cellular therapy with immune effector cells including a variety of lymphocytes, has been developed at research centers around the world.
Chimeric antigen receptor CAR T-cell have emerged from the lab as FDA-approved treatments for a variety of cancers. This includes some gene-modified T cells and natural (NK) cells. The future for effector cell therapy is bright, as it becomes the treatment of choice for many cancer patients. Baylor Scott & White Health will continue to play a leading role in these pioneering efforts.
Contact our patient nurse navigators in the Dallas area at 214.820.3535 or in the Temple area at 254.724.5918 for more information about CAR T and immune effector cell therapies and clinical trials.
Learn more about CAR T-cell therapy